Abstract Number: 1858 • 2019 ACR/ARP Annual Meeting
Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: Beta-2-glycoprotein-I(b2GPI), an apolipoprotein abundant in plasma, is readily expressed in human atherosclerotic plaque. Anti-b2GPI-IgA antibodies (Ab) have been previously reported in both rheumatoid arthritis…Abstract Number: 1859 • 2019 ACR/ARP Annual Meeting
Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Background/Purpose: A tender joint count is part of most disease activity scores and remission criteria in rheumatoid arthritis (RA). A recent study in established RA…Abstract Number: 1860 • 2019 ACR/ARP Annual Meeting
Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Background/Purpose: Gout is a highly prevalent form of inflammatory arthritis associated with increased morbidity and mortality, and the burden of gout on the healthcare system…Abstract Number: 1861 • 2019 ACR/ARP Annual Meeting
Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatologic diseases. In our prior study of rheumatoid arthritis patients and hospital admissions,…Abstract Number: 1862 • 2019 ACR/ARP Annual Meeting
Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making
Background/Purpose: Treat to Target (T2T) opportunities and rheumatologist decision making are not defined, captured, or reportable within existing electronic health record (EHR) software. We developed…Abstract Number: 1863 • 2019 ACR/ARP Annual Meeting
Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients
Background/Purpose: To improve Pneumococcal Vaccination rates in high risk Rheumatology patients on immunosuppressive therapy.Methods: The study was a quality improvement project based on the pre-post-intervention…Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…Abstract Number: 1866 • 2019 ACR/ARP Annual Meeting
Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Background/Purpose: Dermatomyositis (DM) is a complex immune-mediated disease resulting in muscle and skin inflammation. Prior studies of gene expression in DM have revealed a type…Abstract Number: 1867 • 2019 ACR/ARP Annual Meeting
Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status
Background/Purpose: Skeletal muscle, pulmonary and articular involvement in idiopathic inflammatory myopathies (IIM) limit the mobility/self-sufficiency of patients, and can have a negative impact on body…Abstract Number: 1868 • 2019 ACR/ARP Annual Meeting
Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory myopathy characterized by prominent vascular and perivascular inflammation in affected skeletal muscles. The mechanisms of vessel injury in…Abstract Number: 1869 • 2019 ACR/ARP Annual Meeting
Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders
Background/Purpose: Dermatomyositis (DM) is an autoimmune disease affecting the skin, skeletal muscle, lungs, and/or other organs. While the pathogenesis remains poorly understood, it is thought…Abstract Number: 1870 • 2019 ACR/ARP Annual Meeting
NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis
Background/Purpose: Differentiating smouldering disease activity from weakness due to fatty replacement of atrophied muscle can often be a challenge in Idiopathic Inflammatory Myositis (IIM). There…Abstract Number: 1871 • 2019 ACR/ARP Annual Meeting
Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury
Background/Purpose: Myositis-specific antibodies (MSAs) are identified in over half of children with JDM and are associated with distinct clinical phenotypes. MSA subtype, in combination with…Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting
Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014
Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…
ACR Meeting Abstracts